Overview

A Study of YM178 in Patients With Symptomatic Overactive Bladder

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Mirabegron